Skip to content

IRONWOOD PHARMACEUTICALS, INC.: 10-Q filed 2017-05-08

What IRONWOOD PHARMACEUTICALS, INC. reported in its quarterly report filed 2017-05-08 (fiscal Q1 2017): 29 published measures, 57 facts as tagged in accession 0001558370-17-003785.

This filing

Form
10-Q (quarterly report)
Filed
2017-05-08
Fiscal period
fiscal Q1 2017
Accession
0001558370-17-003785 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All IRONWOOD PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-03-31701,319,000USD
At 2016-12-31709,821,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-03-3129,637,000USD
At 2016-12-3166,716,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-03-31133,319,000USD
At 2016-12-3154,004,000USD
At 2016-03-31280,926,000USD
At 2015-12-31261,287,000USD

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-03-311,037,000USD90
2016-01-01 to 2016-03-311,008,000USD91

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-01-01 to 2017-03-3152,166,000USD90
2016-01-01 to 2016-03-3166,042,000USD91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-03-31-1,244,324,000USD
At 2016-12-31-1,191,823,000USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-03-3118,633,000USD
At 2016-12-3120,512,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-03-317,279,000USD90
2016-01-01 to 2016-03-316,806,000USD91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-39,705,000USD90
2016-01-01 to 2016-03-31-1,968,000USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-03-31357,853,000USD
At 2016-12-31380,181,000USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-01-01 to 2017-03-318,983,000USD90
2016-01-01 to 2016-03-319,907,000USD91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-03-3178,893,000USD
At 2016-12-3191,131,000USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2017-03-31785,000USD
At 2016-12-31785,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-03-311,152,000USD
At 2016-12-31933,000USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2017-03-311,513,000USD
At 2016-12-311,081,000USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2017-01-01 to 2017-03-31531,000USD90

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2017-01-01 to 2017-03-3155,604,000USD90
2016-01-01 to 2016-03-3136,168,000USD91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-01-01 to 2017-03-3133,702,000USD90
2016-01-01 to 2016-03-3131,842,000USD91

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-03-31-41,000USD
At 2016-12-31-7,000USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2017-03-31165,699,000USD
At 2016-12-31166,119,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-03-31783,000USD
At 2016-12-311,456,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-03-318,190,000USD
At 2016-12-318,190,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-03-318,664,000USD
At 2016-12-319,030,000USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-52,535,000USD90
2016-01-01 to 2016-03-31-13,182,000USD91

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-52,501,000USD90
2016-01-01 to 2016-03-31-13,297,000USD91

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2017-01-01 to 2017-03-312,910,000USD90
2016-01-01 to 2016-03-312,833,000USD91

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2017-01-01 to 2017-03-31420,000USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-12,796,000USD90
2016-01-01 to 2016-03-31-11,329,000USD91

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-71,000USD90

Inspect the source

Entity
IRONWOOD PHARMACEUTICALS, INC. / CIK 0001446847
Captured
2026-09-20T09:04:45.983Z
SEC response SHA-256
e907547bc46d38e028ac317d678e19520bc4135085f9133b1b1f54dc9a6016a4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001446847.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))